Once-daily dosing of nevirapine in HAART

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 1, 2008, Pages 13-16

  Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

DAUFIN; Efficacy; Safety; Twice daily

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; LIVER TOXICITY; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; RISK BENEFIT ANALYSIS; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE; VIRAL LOAD;

EID: 37549022243     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm432     Document Type: Article

References (19)

1. Gazzard B, Bernard AJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2006; 7: 487-503.
2. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-43.
3. U.S. Department of Health and Human Services. Panel on Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2006 (6 June 2007, date last accessed).
4. Waters L, John L, Nelson M. Non-nucleoside reverse transcriptase inhibitors: A review. Int J Clin Pract 2007; 61: 105-18.
5. Barreiro P, de Mendoza C, Gonzalez-Lahoz J et al. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption. Clin Infect Dis 2005; 41: 897-900.
6. Rey D, Schmitt M, Holsey G et al. Early virologic non-response to once daily combination of lamivudine, tenofovir and nevirapine in antiretroviral naive HIV-infected patients: Preliminary results of the DAUIFIN study. In: Abstracts of the Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007. Abstract 503.
7. Viramune® EU. Summary of Product Characteristics. Boehringer Ingelheim. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Viramune/ H-183-PI-en.pdf (6 June 2007, date last accessed).
8. Brenner BG, Oliveira M, Doualla-Bell F et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20: F9-13.
9. Towner W, Kerrigan HL, LaRiviere M et al. Efficacy of a once daily (QD) regimen of nevirapine (NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naive HIV infected patients: A pilot study. In: Abstracts of the Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2004. Abstract P49.
10. Droste JA, Kearney BP, Hekster YA et al. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41: 37-43.
11. Schewe CK, Noah C, Adam A et al. Switch to antiretroviral regimens containing tenofovir (TDF) and nevirapine (NVP). A retrospective analysis of efficacy and tolerability. In: Tenth European AIDS Conference, Dublin, Ireland, 2005. Poster PE 7.5/6.
12. Bonjoch A, Paredes R, Domingo P et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006; 22: 321-9.
13. Wit FW, Phanuphak P, Ruxrungtham K et al. A randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine, or efavirenz, together with stavudine and lamivudine. Three-year extended follow-up of the 2NN Study. In: Abstracts of the Fourth International AIDS Society Conference, Sydney, Australia, 2007 Abstract WEPEB032.
14. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63.
15. Martinez E, Arnaiz JA Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-46.
16. Kruse W, Rampmaier J, Ullrich G et al. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994, 32: 452-7.
17. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
18. Cooper CL, van Heeswiik RP. Once-daily nevirapine dosing: A pharmacokinetics, efficacy and safety review. HIV Med 2007; 8 1-7.
19. Negredo E, Molto J, Munoz-Moreno JA et al. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir Ther 2004; 9: 335-42.